Voyageur Pharmaceuticals (TSE:VM)
:VM
Want to see TSE:VM full AI Analyst Report?
VM Stock Chart & Stats
C$0.17
>-C$0.01(-5.56%)
At close: 4:00 PM EST
C$0.17
>-C$0.01(-5.56%)
Day’s Range― - ―
52-Week RangeC$0.10 - C$0.36
Previous CloseN/A
Volume12.11K
Average Volume (3M)72.03K
Market Cap
C$18.75M
Enterprise ValueC$18.72M
Total Cash (Recent Filing)C$75.71K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta-0.60
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding178,586,980
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth of ~165% signals meaningful commercialization progress beyond one-off sales. Over the next 2–6 months, this trend supports scale economies if maintained, validating product-market fit and providing a foundation to improve margins as fixed costs are absorbed.
Low LeverageA lightly levered balance sheet reduces near-term solvency risk and preserves flexibility to raise capital or fund operations via equity if needed. This structural cushion matters over the medium term while the business converts rising revenue into sustainable profitability.
Specialized Product FocusA focused strategy on mineral-derived barium sulfate for medical imaging targets a specialized, regulated market with structural demand. Proprietary supply and processing capabilities can create durable differentiation and barriers to entry if qualification and regulatory pathways progress.
Bears Say
Negative MarginsDeeply negative gross margins and large operating losses indicate the business is not yet covering variable or fixed costs. Over months this undermines internal funding ability, requires continual external financing, and delays the onset of sustainable unit economics until margins materially improve.
Weak Cash GenerationMeaningfully negative operating and free cash flow shows the company is burning cash in line with accounting losses. This persistent cash burn creates reliance on external funding rounds, heightens dilution risk, and constrains investment cadence and commercialization unless cash generation turns positive.
Equity Erosion / Negative ROEDeclining equity and negative ROE reflect cumulative losses that erode the shareholder cushion. Over the medium term this reduces balance-sheet resilience, limits borrowing capacity, and increases likelihood of dilutive capital raises to sustain operations and commercialization efforts.
Voyageur Pharmaceuticals News
VM FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.10 and its highest was C$0.36 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$18.75M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 98 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 178,586,980 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
Technical Analysis
Options Prices
Currently, No data available
---